GT201600050A - Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso - Google Patents
Nanopartículas poliméricas terapéuticas y métodos para su elaboración y usoInfo
- Publication number
- GT201600050A GT201600050A GT201600050A GT201600050A GT201600050A GT 201600050 A GT201600050 A GT 201600050A GT 201600050 A GT201600050 A GT 201600050A GT 201600050 A GT201600050 A GT 201600050A GT 201600050 A GT201600050 A GT 201600050A
- Authority
- GT
- Guatemala
- Prior art keywords
- methods
- preparation
- polymeric nanoparticles
- therapeutic polymeric
- nanoparticles
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- QYZOGCMHVIGURT-UHFFFAOYSA-N AZD-1152 Chemical compound N=1C=NC2=CC(OCCCN(CCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 QYZOGCMHVIGURT-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361878227P | 2013-09-16 | 2013-09-16 | |
| US201461939332P | 2014-02-13 | 2014-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201600050A true GT201600050A (es) | 2019-08-12 |
Family
ID=51619214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201600050A GT201600050A (es) | 2013-09-16 | 2016-03-10 | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso |
Country Status (38)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| DK3104838T3 (da) * | 2014-02-13 | 2020-02-24 | Pfizer | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf |
| WO2017081606A1 (en) * | 2015-11-10 | 2017-05-18 | Pfizer Inc. | Methods of determining features of polymeric nanoparticles that include a therapeutic agent |
| WO2017089942A1 (en) * | 2015-11-25 | 2017-06-01 | Pfizer Inc. | Therapeutic nanoparticles comprising an antibiotic and methods of making and using same |
| JP6579948B2 (ja) * | 2015-12-24 | 2019-09-25 | 株式会社日立ハイテクノロジーズ | 生体ポリマを分析するための測定試薬及び分析デバイス |
| ES2797302T3 (es) * | 2016-03-22 | 2020-12-01 | Pfizer | Procedimiento para la preparación de nanopartículas terapéuticas |
| JP7082110B2 (ja) | 2017-03-29 | 2022-06-07 | テルモ株式会社 | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット |
| TW202023568A (zh) | 2018-07-30 | 2020-07-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| TW202019440A (zh) | 2018-07-30 | 2020-06-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| EP3860577A4 (en) * | 2019-02-02 | 2022-08-10 | Nanobrid Innovations Private Limited | LIPID-POLYMER HYBRID NANOPARTICLE |
| US11123734B2 (en) | 2019-07-31 | 2021-09-21 | CytoVale Inc. | System and method for immune activity determination |
| WO2021037933A1 (en) | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2021224381A1 (en) | 2020-05-07 | 2021-11-11 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
| WO2022192139A1 (en) | 2021-03-10 | 2022-09-15 | Astrazeneca Ab | Aurora kinase b inhibitors for use for treating cancer |
| US11548003B1 (en) * | 2022-01-13 | 2023-01-10 | CytoVale Inc. | System and method for determining an immune activation state |
| US11592371B1 (en) | 2022-01-13 | 2023-02-28 | CytoVale Inc. | System and method for determining an immune activation state |
| US11964281B2 (en) | 2022-02-03 | 2024-04-23 | CytoVale Inc. | System and method for correcting patient index |
| WO2023150246A1 (en) * | 2022-02-04 | 2023-08-10 | Virginia Commonwealth University | Sustained release formulations and methods of use thereof |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| GB9017479D0 (en) | 1990-08-09 | 1990-09-26 | Ici Plc | Process |
| GB9102727D0 (en) | 1991-02-08 | 1991-03-27 | Ici Plc | Pharmaceutical agent |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (enExample) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| DK0752245T3 (da) | 1995-07-05 | 2002-09-09 | Europ Economic Community | Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| HK1039126B (en) | 1998-10-08 | 2005-09-30 | 阿斯特拉曾尼卡有限公司 | Quinazoline derivatives |
| FI982733L (fi) | 1998-12-17 | 2000-06-18 | Orion Yhtymae Oyj | Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| CZ20021009A3 (cs) | 1999-09-21 | 2002-06-12 | Astrazeneca Ab | Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| IL153246A0 (en) | 2000-06-28 | 2003-07-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1372385A1 (en) | 2001-03-30 | 2004-01-02 | Rhodia Inc. | Aqeuous suspension of nanoparticles comprising an agrochemical active ingredient |
| US7132427B2 (en) | 2001-06-21 | 2006-11-07 | Ariad Pharmaceuticals, Inc. | Quinazolines and uses thereof |
| GB0124299D0 (en) | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
| DE60222160T2 (de) | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
| NZ533440A (en) | 2001-12-24 | 2006-08-31 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
| JP4448441B2 (ja) | 2002-06-05 | 2010-04-07 | ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド | 眼科用医薬のデリバリーシステム |
| EP2283864A1 (en) | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| US8501215B2 (en) | 2002-07-31 | 2013-08-06 | Guohua Chen | Injectable multimodal polymer depot compositions and uses thereof |
| PT1578755E (pt) * | 2002-12-24 | 2007-10-19 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina e sua utilização farmacêutica |
| CA2520475C (en) | 2003-04-03 | 2012-10-09 | Jessie L.-S. Au | Tumor-targeting drug-loaded particles |
| US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| BRPI0412211A (pt) * | 2003-07-23 | 2006-08-22 | Pr Pharmaceuticals Inc | composições de liberação controlada |
| US9028829B2 (en) | 2004-02-20 | 2015-05-12 | The Children's Hospital Of Philadelphia | Uniform field magnetization and targeting of therapeutic formulations |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| US8945629B2 (en) | 2004-09-10 | 2015-02-03 | University Of Wyoming | Nanoparticles for cytoplasmic drug delivery to cancer cells |
| JP2008535924A (ja) | 2005-04-12 | 2008-09-04 | エラン ファーマ インターナショナル リミテッド | ナノ粒子キナゾリン誘導体製剤 |
| US20090022806A1 (en) | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
| CA2626016A1 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| WO2010009146A1 (en) | 2008-07-15 | 2010-01-21 | University Of Kansas | Nanoclusters for delivery of poorly water soluble drug nanoparticles |
| JP5131971B2 (ja) | 2005-12-26 | 2013-01-30 | 株式会社Ｌｔｔバイオファーマ | 水溶性非ペプチド性低分子薬物含有ナノ粒子 |
| WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| JP5630998B2 (ja) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
| GB0609617D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Process & intermediate |
| GB0609621D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| US20110052697A1 (en) | 2006-05-17 | 2011-03-03 | Gwangju Institute Of Science & Technology | Aptamer-Directed Drug Delivery |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| EP2050449A4 (en) | 2006-07-31 | 2010-10-06 | Senju Pharma Co | AQUEOUS LIQUID PREPARATION WITH AN AMID COMPOUND |
| US20100144845A1 (en) | 2006-08-04 | 2010-06-10 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
| WO2008147456A2 (en) | 2006-11-20 | 2008-12-04 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
| WO2008091465A2 (en) | 2006-12-21 | 2008-07-31 | Wayne State University | Peg and targeting ligands on nanoparticle surface |
| CA3201293A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| WO2008124639A2 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
| AU2008240155B2 (en) | 2007-04-13 | 2012-09-20 | University Of North Texas Health Science Center At Fort Worth | Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics |
| US20100129456A1 (en) | 2007-05-14 | 2010-05-27 | Ltt Bio-Pharma Co., Ltd. | Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group |
| PL2200588T3 (pl) | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
| US8974814B2 (en) | 2007-11-12 | 2015-03-10 | California Institute Of Technology | Layered drug delivery polymer monofilament fibers |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| US20110104052A1 (en) | 2007-12-03 | 2011-05-05 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| KR100961880B1 (ko) | 2007-12-12 | 2010-06-09 | 중앙대학교 산학협력단 | 밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제 |
| US20110182946A1 (en) | 2008-03-17 | 2011-07-28 | Board Of Regents, The University Of Texas System | Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques |
| AU2009234127B2 (en) * | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| US20090312402A1 (en) | 2008-05-20 | 2009-12-17 | Contag Christopher H | Encapsulated nanoparticles for drug delivery |
| CN102099016A (zh) * | 2008-06-16 | 2011-06-15 | 佰恩德生物科学股份有限公司 | 载药的聚合物纳米微粒及其制备和使用方法 |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| JP2012501965A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| EP2309991B1 (en) | 2008-06-16 | 2019-03-06 | Pfizer Inc | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| WO2010005740A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles |
| US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
| US9333163B2 (en) | 2008-10-06 | 2016-05-10 | Massachusetts Institute Of Technology | Particles with multiple functionalized surface domains |
| US20110125090A1 (en) | 2008-11-13 | 2011-05-26 | Peyman Gholam A | Ophthalmic drug delivery system and method |
| US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| EP2379064B1 (en) | 2008-12-15 | 2020-02-26 | Pfizer Inc. | Long circulating nanoparticles for sustained release of therapeutic agents |
| CA2749945A1 (en) * | 2009-01-31 | 2010-08-05 | Abbott Laboratories | Markers to predict and monitor response to aurora kinase b inhibitor therapy |
| US20120052041A1 (en) | 2009-02-04 | 2012-03-01 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
| CA2768968A1 (en) * | 2009-09-29 | 2011-04-07 | Eyegate Pharmaceuticals, Inc. | Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| ES2780156T3 (es) * | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
| EA201290497A1 (ru) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых |
| WO2011084521A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same |
| ES2384060B1 (es) | 2010-03-24 | 2013-09-23 | Lipotec S.A. | Cápsulas de nanopartículas lipídicas. |
| WO2011119262A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
| US20110293700A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP2611466B1 (en) | 2010-08-30 | 2019-06-12 | President and Fellows of Harvard College | Shear controlled release of thrombolytic therapies for stenotic lesions |
| WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| ES2386177B1 (es) | 2010-09-21 | 2013-09-23 | Lipotec, S.A. | Nanocapsulas conteniendo microemulsiones |
| WO2012040513A1 (en) | 2010-09-22 | 2012-03-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for the delivery of beta lapachone |
| EP2627317A4 (en) | 2010-10-15 | 2014-08-20 | Glaxo Group Ltd | MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE |
| EA201390600A1 (ru) | 2010-10-22 | 2013-09-30 | Байнд Терапьютикс, Инк. | Терапевтические наночастицы с сополимерами с большим молекулярным весом |
| KR101304597B1 (ko) | 2010-11-02 | 2013-09-12 | 한남대학교 산학협력단 | 멀티-코어 구조를 갖는 생체적합성 입자의 제조방법 및 이에 의해 제조된 멀티-코어 구조를 갖는 생체적합성 입자 |
| FR2967581B1 (fr) | 2010-11-19 | 2012-12-28 | Sanofi Aventis | Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques |
| ES2712779T3 (es) | 2011-01-24 | 2019-05-14 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Nanopartículas para la administración dérmica y sistémica de fármacos |
| US20140035438A1 (en) | 2011-04-12 | 2014-02-06 | Massachusetts Institute Of Technology | Passive, Self-Tuning Energy Harvester for Extracting Energy From Rotational Motion |
| JP2014531456A (ja) | 2011-09-22 | 2014-11-27 | バインド セラピューティックス インコーポレイテッド | 治療用ナノ粒子と癌を治療する方法 |
| WO2013090840A1 (en) | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors |
| US10561733B2 (en) | 2012-02-29 | 2020-02-18 | Merck Patent Gmbh | Process for producing nanoparticles laden with active ingredient |
| EP2825207B1 (en) | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
| WO2014043625A1 (en) * | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| CN105102442B (zh) * | 2013-03-18 | 2018-11-09 | 基因科学医药公司 | 作为抗癌药的喹啉衍生物 |
-
2014
- 2014-09-12 ES ES17181565T patent/ES2784423T3/es active Active
- 2014-09-12 MX MX2016003437A patent/MX370490B/es active IP Right Grant
- 2014-09-12 SG SG11201601218PA patent/SG11201601218PA/en unknown
- 2014-09-12 PT PT171815657T patent/PT3311845T/pt unknown
- 2014-09-12 EP EP17181565.7A patent/EP3311845B1/en active Active
- 2014-09-12 SI SI201430374T patent/SI3046584T1/sl unknown
- 2014-09-12 SM SM20170442T patent/SMT201700442T1/it unknown
- 2014-09-12 HU HUE17181565A patent/HUE048498T2/hu unknown
- 2014-09-12 PL PL17181565T patent/PL3311845T3/pl unknown
- 2014-09-12 BR BR112016004922-5A patent/BR112016004922B1/pt active IP Right Grant
- 2014-09-12 PT PT147724207T patent/PT3046584T/pt unknown
- 2014-09-12 EP EP14772420.7A patent/EP3046584B1/en active Active
- 2014-09-12 CA CA2922279A patent/CA2922279C/en active Active
- 2014-09-12 RS RS20200361A patent/RS60093B1/sr unknown
- 2014-09-12 TN TN2016000077A patent/TN2016000077A1/en unknown
- 2014-09-12 DK DK17181565.7T patent/DK3311845T3/da active
- 2014-09-12 CN CN201480050773.9A patent/CN105555315B/zh active Active
- 2014-09-12 ES ES14772420.7T patent/ES2640648T3/es active Active
- 2014-09-12 MY MYPI2016700906A patent/MY191804A/en unknown
- 2014-09-12 RS RS20170945A patent/RS56362B1/sr unknown
- 2014-09-12 RU RU2016110351A patent/RU2682332C2/ru active
- 2014-09-12 AU AU2014320088A patent/AU2014320088B2/en active Active
- 2014-09-12 ME MEP-2017-231A patent/ME02860B/me unknown
- 2014-09-12 HR HRP20171365TT patent/HRP20171365T1/hr unknown
- 2014-09-12 PE PE2016000354A patent/PE20160930A1/es unknown
- 2014-09-12 AP AP2016009088A patent/AP2016009088A0/xx unknown
- 2014-09-12 SI SI201431532T patent/SI3311845T1/sl unknown
- 2014-09-12 HU HUE14772420A patent/HUE034490T2/en unknown
- 2014-09-12 DK DK14772420.7T patent/DK3046584T3/en active
- 2014-09-12 KR KR1020167009468A patent/KR102307175B1/ko active Active
- 2014-09-12 LT LTEP14772420.7T patent/LT3046584T/lt unknown
- 2014-09-12 SM SM20200162T patent/SMT202000162T1/it unknown
- 2014-09-12 WO PCT/GB2014/052787 patent/WO2015036792A1/en not_active Ceased
- 2014-09-12 JP JP2016542377A patent/JP6543258B2/ja active Active
- 2014-09-12 PL PL14772420T patent/PL3046584T3/pl unknown
- 2014-09-12 LT LTEP17181565.7T patent/LT3311845T/lt unknown
- 2014-09-15 UY UY35738A patent/UY35738A/es not_active Application Discontinuation
- 2014-09-15 TW TW103131811A patent/TWI644674B/zh active
- 2014-09-15 US US14/485,875 patent/US10047072B2/en active Active
-
2016
- 2016-02-18 IL IL244174A patent/IL244174B/en active IP Right Grant
- 2016-03-10 CL CL2016000556A patent/CL2016000556A1/es unknown
- 2016-03-10 DO DO2016000061A patent/DOP2016000061A/es unknown
- 2016-03-10 GT GT201600050A patent/GT201600050A/es unknown
- 2016-03-11 NI NI201600037A patent/NI201600037A/es unknown
- 2016-03-14 CR CR20160130A patent/CR20160130A/es unknown
- 2016-03-14 PH PH12016500499A patent/PH12016500499B1/en unknown
- 2016-04-04 ZA ZA2016/02201A patent/ZA201602201B/en unknown
-
2017
- 2017-07-27 AU AU2017208307A patent/AU2017208307B2/en active Active
- 2017-09-13 CY CY20171100964T patent/CY1119398T1/el unknown
- 2017-09-27 ZA ZA2017/06497A patent/ZA201706497B/en unknown
-
2018
- 2018-06-27 US US16/019,982 patent/US10577351B2/en active Active
-
2020
- 2020-03-12 HR HRP20200407TT patent/HRP20200407T1/hr unknown
- 2020-12-24 IL IL279767A patent/IL279767B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201600050A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso | |
| DK3706796T3 (da) | Eksosomerer som RNA terapeutikske midler | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| IL249837B (en) | Inhaler for pulmonary delivery of active agents | |
| BR112016000489A2 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2015002891A1 (es) | Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales. | |
| MX385842B (es) | Conjugados de partículas de tipo virus y uso de las mismas. | |
| MX380204B (es) | Micrordenamiento para suministro de agente terapeútico y métodos de uso. | |
| EP2988781A4 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
| MX379193B (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| AR091959A1 (es) | Agentes de sosten sinteticos y agentes de sosten monodispersos y metodos para la elaboracion de los mismos | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| MX386584B (es) | Composiciones de liberación retardada de linaclotida. | |
| CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
| CL2015001246A1 (es) | Derivados de bendamustina y los metodos de su uso | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
| PT2859896T (pt) | Composições farmacêuticas para o tratamento de distúrbios musculares | |
| PT2991633T (pt) | Terapia com bacteriófagos | |
| CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
| PT3511004T (pt) | Preparações combinadas para o tratamento de cancro | |
| UY35747A (es) | Derivados sustituidos de fenilalanina | |
| CL2016000038A1 (es) | Piraxolo-piridinaminas sustituidas |